Biotech entity
Every one of those 2 sits in a single category, fda-approval. Of the tracked stories, 2 of 2 also mention Donald Trump, the most common co-covered peer. We currently track 2 Biotech stories that mention Michael Davis, all published on September 9, 2026.
Last mentioned: 2d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, fda-approval. Of the tracked stories, 2 of 2 also mention Donald Trump, the most common co-covered peer. We currently track 2 Biotech stories that mention Michael Davis, all published on September 9, 2026. Each carries 2 original sources on average.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 5 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Michael Davis. Shared-story counts are live from our verified record — not editorial picks.
HHS announces permanent FDA center directors
Four senior positions filled, including permanent directors for drugs, vaccines/biologics, and tobacco products.
HHS fills four senior FDA roles
The Department of Health and Human Services announced permanent directors for the FDA's drug, vaccine and biologics, and tobacco centers, along with a fourth senior position.
Tracy Beth Høeg departs CDER
Høeg says she was fired as director of the FDA's Center for Drug Evaluation and Research.
Michael Davis assumes acting CDER director
Davis steps in as acting director of CDER following Høeg's departure.
Michael Davis returns to FDA as deputy director
Davis rejoins the agency after working at a nonprofit pursuing psychedelic drug development.
A former psychiatric drug regulator with psychedelic nonprofit experience now leads FDA's drug center as Trump and RFK push faster reviews. Biopharma teams should watch psilocybin, MDMA and LSD programs plus the new vaccines center director.
Source: whec.com · orlandosentinel.com
The FDA's new permanent CDER director is Michael Davis, whose psychiatric drug and psychedelic nonprofit background aligns with White House calls for faster psilocybin, MDMA, and LSD reviews. Vaccine and tobacco center leadership also stabilized.
Michael Davis is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
